How do you decide whether to offer tamoxifen or OFS + AI in premenopausal patients with metastatic ER+ HER2+ breast cancer as your endocrine therapy?  

What data may support the routine escalation of endocrine therapy? Should HER2 therapy be prioritized instead?

Answer from: Medical Oncologist at Community Practice
Medical Oncologist at PeaceHealth
I thought the question was about metastatic breast...
Sign in or Register to read more